Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v2.4.1.9
Consolidated Balance Sheets (USD $)
Dec. 31, 2014
Dec. 31, 2013
Current assets:    
Cash and cash equivalents $ 6,262,445us-gaap_CashAndCashEquivalentsAtCarryingValue $ 303,020us-gaap_CashAndCashEquivalentsAtCarryingValue
Prepaid expenses 270,556us-gaap_PrepaidExpenseCurrent 2,500us-gaap_PrepaidExpenseCurrent
Total current assets 6,533,001us-gaap_AssetsCurrent 305,520us-gaap_AssetsCurrent
Restricted cash 13,728us-gaap_RestrictedCashAndCashEquivalentsNoncurrent  
Property and equipment, net 54,044us-gaap_PropertyPlantAndEquipmentNet  
Total assets 6,600,773us-gaap_Assets 305,520us-gaap_Assets
Current liabilities:    
Accounts payable 344,160us-gaap_AccountsPayableCurrent 181,471us-gaap_AccountsPayableCurrent
Accrued interest payable   77,140us-gaap_InterestPayableCurrent
Accrued expenses 249,491us-gaap_AccruedLiabilitiesCurrent 63,488us-gaap_AccruedLiabilitiesCurrent
Derivative warrant liability   19,932us-gaap_DerivativeLiabilitiesCurrent
Notes payable-current 144,389us-gaap_NotesPayableCurrent 306,835us-gaap_NotesPayableCurrent
Total current liabilities 738,040us-gaap_LiabilitiesCurrent 648,866us-gaap_LiabilitiesCurrent
Notes payable   331,243us-gaap_LongTermNotesPayable
Total liabilities 738,040us-gaap_Liabilities 980,109us-gaap_Liabilities
Commitments and Contingencies      
Stockholders' equity (deficit)    
Preferred Stock $0.0001 par value:10,000,000 share authorized, no shares issued and outstanding at December 31, 2014      
Common stock, $0.0001 par value; 150,000,000 shares authorized, 25,938,332 and 6,964,788 shares issued and outstanding at December 31, 2014 and December 31, 2013 2,594us-gaap_CommonStockValue 696us-gaap_CommonStockValue
Additional paid-in capital 10,287,214us-gaap_AdditionalPaidInCapital 102,696us-gaap_AdditionalPaidInCapital
Accumulated deficit (4,427,075)us-gaap_RetainedEarningsAccumulatedDeficit (1,886,590)us-gaap_RetainedEarningsAccumulatedDeficit
Total stockholders' equity (deficit) 5,862,733us-gaap_StockholdersEquity (1,783,198)us-gaap_StockholdersEquity
Total liabilities, preferred stock and stockholders equity (deficit) 6,600,773us-gaap_LiabilitiesAndStockholdersEquity 305,520us-gaap_LiabilitiesAndStockholdersEquity
Series A Convertible Preferred Stock [Member]    
JB Therapeutics' Series A Preferred Stock, $0.0001 Par Value:    
Preferred stock, value   1,106,609us-gaap_TemporaryEquityCarryingAmountAttributableToParent
/ us-gaap_StatementClassOfStockAxis
= crbp_SeriesAConvertiblePreferredStockMember
Series A Non-Convertible Preferred Stock [Member]    
JB Therapeutics' Series A Preferred Stock, $0.0001 Par Value:    
Preferred stock, value   $ 2,000us-gaap_TemporaryEquityCarryingAmountAttributableToParent
/ us-gaap_StatementClassOfStockAxis
= crbp_SeriesANonConvertiblePreferredStockMember